Phase 1 Clinical Trial of a Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
Latest Information Update: 09 Oct 2025
At a glance
- Drugs Cancer vaccines (Primary) ; Poly ICLC (Primary) ; Nivolumab
- Indications Bladder cancer; Carcinoma
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 19 Sep 2025 Planned End Date changed from 30 Sep 2033 to 31 Mar 2033.
- 24 Mar 2025 Status changed from not yet recruiting to recruiting.
- 24 Mar 2025 Planned End Date changed from 31 Oct 2033 to 30 Sep 2033.